Other posters presented at the meeting reported promising efficacy and safety results from small series of pediatric patients with specific, refractory epilepsy syndromes, including 10 children and adolescents with epilepsy in tuberous sclerosis complex, and 9 children and adolescents with refractory epileptic spasms. Both of these studies were run at Massachusetts General Hospital in Boston.
The study received research funding from GW Pharmaceuticals, the company developing the tested formulation of cannabidiol (Epidiolex). Dr. Devinsky and Dr. Oldham had no personal disclosures.
On Twitter @mitchelzoler